Trial Profile

Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab emtansine (Primary) ; Zirconium-89 DFO-trastuzumab (Primary)
Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms ZEPHIR

31 Mar 2025 Status changed from active, no longer recruiting to completed.
20 Apr 2024 This trial has been completed in Netherlands (Global end date: 28 Mar 2024), according to European Clinical trial database record.
11 Apr 2024 This trial has been completed in Belgium (Global end date: 28 Mar 2024).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com